Total trials
349
Active
109
Phase 3
14
Total enrollment
1,474,449
Pipeline matrix
Showing 40 of 62 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Metformin | — | — | — | — | — | 1 | |
| Relmacabtagene Autoleucel | — | — | — | — | — | 1 | |
| standard dose indomethacin | — | — | — | — | — | 1 | |
| low dose indomethacin | — | — | — | — | — | 1 | |
| Adjuvant chemoradiotherapy | — | — | — | — | — | 1 | |
| Adjuvant chemotherapy | — | — | — | — | — | 1 | |
| serplulimab、bevacizumab | — | — | — | — | — | 1 | |
| Probiotics 6600 | — | — | — | — | — | 1 | |
| Fludarabine | — | — | — | — | 2 | ||
| umbilical cord mesenchymal stem cell | — | — | — | — | — | 1 | |
| Hetrombopag | — | — | — | — | — | 1 | |
| Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor | — | — | — | — | — | 1 | |
| Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody | — | — | — | — | — | 1 | |
| Iparomlimab and Tuvonralimab+Lenvatinib + Cisplatin/Carboplatin + Nab-paclitaxel | — | — | — | — | — | 1 | |
| HRS-4642+NALIRIFOX | — | — | — | — | — | 1 | |
| HRS-4642+NALIRIFOX+Adebrelimab | — | — | — | — | — | 1 | |
| Irinotecan liposome | — | — | — | — | — | 1 | |
| Oxaliplatin | — | — | — | — | — | 1 | |
| 5-FU | — | — | — | — | — | 1 | |
| LV | — | — | — | — | — | 1 | |
| Cyclophosphamide | — | — | — | — | — | 1 | |
| Mutant KRAS G12V-specific TCR transduced autologous T cells | — | — | — | — | — | 1 | |
| Anti-PD-1 monoclonal antibody | — | — | — | — | — | 1 | |
| Gemcitabine, Cisplatin | — | — | — | — | — | 1 | |
| Neoadjuvant Gemcitabine + Cisplatin Chemotherapy | — | — | — | — | — | 1 | |
| Furmonertinib | — | — | — | — | — | 1 | |
| anti-CD19 CAR NK cells | — | — | — | — | 4 | ||
| LioCyx-M | — | — | — | — | — | 1 | |
| Anti-CEA CAR-T Cells | — | — | — | — | — | 1 | |
| CL-NK-001 | — | — | — | — | — | 1 | |
| Autologous Neoantigen-Pulsed Dendritic Cell Vaccine | — | — | — | — | — | 1 | |
| CL-NK-003 | — | — | — | — | — | 1 | |
| anti-CD19/BCMA U CAR T cells | — | — | — | — | — | 1 | |
| CD19/BCMA CAR NK | — | — | — | — | — | 1 | |
| SCRT+Capoex+QL706 | — | — | — | — | — | 1 | |
| LCRT+Capoex+QL706 | — | — | — | — | — | 1 | |
| anti-CD19/BCMA U CAR T | — | — | — | — | — | 1 | |
| Medical therapy alone | — | — | — | — | — | 2 | |
| ADT combined with abiraterone | — | — | — | — | — | 2 | |
| 3L PEG | — | — | — | — | 3 |
22 more active programs hidden
Next readouts
- 2023-12-25
- 2024-02-29
- 2025-03-01
- 2025-04-01
- 2025-06
- 2025-07-01
- 2025-08-31
- 2025-09
- 2025-09-01
- 2025-09-01
Top conditions
- Chronic Pancreatitis30
- Pancreatic Cancer24
- Capsule Endoscopy9
- Pancreatitis, Chronic7
- Colorectal Cancer7
- Bladder Cancer6
- Bowel Preparation Scale6
- Adenoma Detection Rate6
Frequently asked questions about Changhai Hospital
- How many clinical trials does Changhai Hospital have on ClinicalTrials.gov?
- Changhai Hospital is listed as the lead sponsor on 349 clinical trials in ClinicalTrials.gov, 109 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Changhai Hospital's trials are in Phase 3?
- 14 of Changhai Hospital's trials are in Phase 3, spread across 62 active drug programs.
- What therapeutic areas does Changhai Hospital focus on?
- Changhai Hospital's most-studied conditions on ClinicalTrials.gov are Chronic Pancreatitis, Pancreatic Cancer, Capsule Endoscopy, Pancreatitis, Chronic, Colorectal Cancer.
- When are Changhai Hospital's next clinical trial readouts?
- Changhai Hospital has 10 upcoming primary-completion readouts tracked here; the soonest is “Anti-CEA CAR-T Cells to Treat Colorectal Liver Metastases”, expected around 2023-12-25.